3 results match your criteria: "General Hospital of Jinan Military Command Region[Affiliation]"
Detection and Identification of Serum Peptides Biomarker in Papillary Thyroid Cancer.
Med Sci Monit
March 2018
Department of Laboratory Medicine, General Hospital of Jinan Military Command Region, Jinan, Shandong, China (mainland).
Article Synopsis
- Papillary thyroid cancer (PTC) is the most common endocrine cancer, and its incidence has increased significantly, highlighting the need for noninvasive biomarkers for early detection.
- Researchers analyzed serum samples from 88 PTC patients and 80 cancer-free individuals using advanced mass spectrometry techniques and developed models to distinguish between the two groups.
- Six peptide ions were identified as potential biomarkers, particularly fragments of fibrinogen and complement component 4A/B, which showed promise in classifying and diagnosing PTC accurately.
Diagnostic accuracy of MALDI-TOF mass spectrometry for non-small cell lung cancer: a meta-analysis.
Biomarkers
May 2018
Department of Laboratory Medicine, General Hospital of Jinan Military Command Region, Jinan, China.
To assess the overall accuracy of matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) in identifying non-small cell lung cancer (NSCLC). A comprehensive search of PubMed, EMBASE and CNKI databases as well as the reference lists from relevant articles was performed prior to July 2017. Two authors independently screened articles based on inclusion and exclusion criteria and assessed the quality of each study using the Quality Assessment of Diagnostic Accuracy Studies 2 (QADAS-2) tool.
View Article and Find Full Text PDFPostoperative infection and survival in osteosarcoma patients: Reconsideration of immunotherapy for osteosarcoma.
Mol Clin Oncol
May 2015
Department of Orthopaedic Surgery, General Hospital of Jinan Military Command Region, Jinan, Shandong 250031, P.R. China.
There is controversy regarding the impact of infection on long-term prognosis in osteosarcoma patients. Clinical trials and experiments relating to this field could bring reconsideration of immunotherapy for osteosarcoma. The clinical records were reviewed of 125 osteosarcoma patients with a mean follow-up of 5.
View Article and Find Full Text PDF